SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
ANTIVIRAL STRATEGIES FOR TREATMENT AND PREVENTIONS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
INTRODUCTIONS (Part 1)
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF (ABSTRACT
191)
Moti N. Ramgopal
Midway Immunology and Research Center, Fort Pierce, FL, United States
EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNTS (ABSTRACT
192)
Kathleen E. Squires
Merck & Co, Inc, North Wales, PA, United States
LENACAPAVIR WITH bNAbs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV (ABSTRACT
193)
Joseph J. Eron
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION (ABSTRACT
194)
Marianne Martinello
University of New South Wales, Sydney, Australia
QUESTIONS AND ANSWERS (Part 1)
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV (ABSTRACT
195)
Emma Rubenstein
University of Paris Cité, Paris, France
SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL (ABSTRACT
196)
Jean-Michel Molina
University of Paris Cité, Paris, France
SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL (ABSTRACT
197)
Anthony M. Mills
Men's Health Foundation, Los Angeles, CA, United States
D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY (ABSTRACT
198)
Gail Matthews
University of New South Wales, Sydney, Australia
QUESTIONS AND ANSWERS (Part 2)
Anton L. Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
Angela D.M. Kashuba
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
11 of
11
|
